U.S. Markets open in 5 hrs 26 mins

Synthetic Biologics, Inc. Provides Company Overview and Update on Clinical Development in New SNNLive Video Interview with StockNewsNow.com

LOS ANGELES, CA / ACCESSWIRE / September 6, 2017 / StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Jeff Riley, CEO of Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, according to the company's website (see here: www.syntheticbiologics.com). The video interview was recorded at the BioMaryland Pavilion at the BIO International Convention 2017 in San Diego, CA.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Synthetic Biologics, Inc. - Late-stage Clinical Company Developing Therapeutics to Preserve the Microbiome

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.

info@stocknewsnow.com

SOURCE: StockNewsNow.com